ONE-WAYOngoing theme · still written in the latest filings
Research into expanding PPMX-T003 indications to hematologic and solid cancers
An individual development program for PPMX-T003, pursuing expansion into hematologic and solid cancers, including ANKL, and validation of clinical efficacy through collaborative research with multiple universities and investigator-initiated Phase I/II trials.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2021 →Still being written about.
Directionhelps1 helps · 0 hurts · 0 flat